期刊
FRONTIERS IN IMMUNOLOGY
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.812649
关键词
autoantigen; autoantibody; therapeutics; decoy; autoimmune; long QT
类别
Autoimmune diseases are often associated with autoantibodies that target self-antigens. A potential therapeutic approach is to design soluble molecules that can block the binding of these autoantibodies to self-antigens, thereby preventing tissue damage. This review discusses the known decoy molecules, the opportunities provided by monoclonal antibody and structural biology advances, and the challenges in implementing this approach. The potential application of this strategy in cardiac phenotypes, specifically Ro-associated long QT syndrome, is also discussed.
Autoimmune diseases are often associated with autoantibodies that abnormally target self-antigens (autoantigens). An intuitive therapeutic strategy for diseases caused by aAbs is to design decoys, or soluble molecules that target the antigen combining site of these aAbs, thereby blocking binding of aAb to self-antigen and subsequent tissue damage. Here, we review the known decoy molecules of these types, discuss newer technological opportunities afforded by monoclonal antibody and structural biology advances, and discuss the challenges to this approach. Recent opportunities relevant to this approach for cardiac phenotypes, specifically Ro-associated long QT syndrome, are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据